STOCK TITAN
  1. Home
  2. Sec-filings
  3. VBIO
  4. [Form 4] Valion Bio, Inc. Insider Trading Activity

Valion Bio (VBIO) CFO exercises 92 RSUs, holds 618 common shares after conversion

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Valion Bio, Inc. Chief Financial Officer Lisa G. Wolf exercised restricted stock units into common shares in a routine compensation-related transaction. She acquired 92 shares of common stock through conversion of 92 Restricted Stock Units, bringing her direct holdings to 618 common shares. Following the transaction, 551 Restricted Stock Units remain outstanding, which continue to vest over time according to a three-year schedule that began on December 18, 2024.

Positive

  • None.

Negative

  • None.

Insights

CFO equity compensation vests and converts into a small number of shares.

The Form 4 shows Lisa G. Wolf, Chief Financial Officer of Valion Bio, Inc., exercising 92 Restricted Stock Units into 92 shares of common stock. This is a standard equity compensation event, not an open‑market purchase or sale.

After this conversion, she directly holds 618 common shares and 551 Restricted Stock Units. The footnotes explain a three-year vesting schedule starting on December 18, 2024, with quarterly installments. This pattern suggests ongoing, scheduled equity grants rather than discretionary trading activity.

The transaction involves a small number of shares, and there are no indications of a trading plan or large position change in this excerpt. Future company filings may update remaining RSU vesting and any additional equity awards as the schedule progresses.

Insider Wolf Lisa G
Role Chief Financial Officer
Type Security Shares Price Value
Exercise Restricted Stock Units 92 $0.00 --
Exercise Common Stock 92 $0.00 --
Holdings After Transaction: Restricted Stock Units — 551 shares (Direct, null); Common Stock — 618 shares (Direct, null)
Footnotes (1)
  1. Each Restricted Stock Unit is convertible into one share of Common Stock. Fifty percent (50%) of the Restricted Stock Units vested upon the one (1) year anniversary of the date of grant, December 18, 2024 (the "Vesting Commencement Date"), and the balance of the Restricted Stock Units will be vested in a series of eight (8) successive equal quarterly installments measured from the first anniversary of the Vesting Commencement Date such that one hundred percent (100%) of the Restricted Stock Units shall have vested on the third anniversary of the Vesting Commencement Date.
RSUs converted 92 Restricted Stock Units Converted into 92 shares of common stock on June 18, 2026
Common shares held 618 shares Direct common stock holdings after transaction
RSUs remaining 551 Restricted Stock Units Outstanding after the June 18, 2026 conversion
Exercise transactions 1 exercise, 92 shares Exercise or conversion coded M in Form 4 summary
Restricted Stock Units financial
"The filing reports transactions in "Restricted Stock Units" held by the CFO."
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
derivative security financial
"The transaction code description is "Exercise or conversion of derivative security"."
A derivative security is a financial contract whose value comes from the price or performance of something else, such as a stock, bond, commodity, or market index. For investors it acts like an insurance policy or a wager: it can be used to protect against losses, lock in prices, or amplify gains and losses, so it can change a portfolio’s risk and potential return without owning the underlying asset directly.
vesting schedule financial
"The footnote describes quarterly installments and a three-year vesting schedule."
A vesting schedule is a timeline that determines when someone gains full ownership of certain benefits, such as company stock or retirement contributions. Think of it like earning the right to own a gift gradually over time, rather than receiving it all at once. It matters to investors because it affects when they can fully access or sell these benefits, influencing their financial planning and decision-making.
Vesting Commencement Date financial
"Footnotes define the "Vesting Commencement Date" as December 18, 2024."
The vesting commencement date is the starting point when an employee begins earning ownership rights to their promised benefits, such as stock options or retirement contributions. Think of it like the day a savings account is opened—only after this date do the benefits start to grow and become fully available over time. It matters to investors because it marks when the clock begins ticking toward full ownership, affecting the timing and value of these benefits.
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Wolf Lisa G
(Last)(First)(Middle)
1305 E. HOUSTON ST., BLDG 1, STE. 311
(Street)
SAN ANTONIO TEXAS 78205
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
Valion Bio, Inc. [ VBIO ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Financial Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/18/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock06/18/2026M92A(1)618D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Restricted Stock Units(1)06/18/2026M92 (2) (2)Common Stock92$0551D
Explanation of Responses:
1. Each Restricted Stock Unit is convertible into one share of Common Stock.
2. Fifty percent (50%) of the Restricted Stock Units vested upon the one (1) year anniversary of the date of grant, December 18, 2024 (the "Vesting Commencement Date"), and the balance of the Restricted Stock Units will be vested in a series of eight (8) successive equal quarterly installments measured from the first anniversary of the Vesting Commencement Date such that one hundred percent (100%) of the Restricted Stock Units shall have vested on the third anniversary of the Vesting Commencement Date.
/s/ Lisa Wolf06/18/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transaction did Valion Bio (VBIO) report for CFO Lisa G. Wolf?

Valion Bio reported that CFO Lisa G. Wolf exercised 92 Restricted Stock Units into 92 shares of common stock. This was an equity compensation conversion, not an open-market trade, and reflects routine vesting of previously granted RSUs rather than a discretionary stock purchase or sale.

How many Valion Bio (VBIO) shares does the CFO hold after this Form 4 transaction?

After the reported transaction, CFO Lisa G. Wolf directly holds 618 shares of Valion Bio common stock. These shares result from RSU conversions over time, according to the company’s equity compensation plan and the vesting schedule disclosed in the Form 4 footnotes.

What happened to Lisa G. Wolf’s Restricted Stock Units in the latest Valion Bio (VBIO) filing?

Lisa G. Wolf converted 92 Restricted Stock Units into 92 common shares, reducing her RSU balance. Following this transaction, 551 RSUs remain outstanding in her name, continuing to vest based on the multi-year schedule described in the Form 4 footnotes for this equity award.

Is the Valion Bio (VBIO) CFO transaction a stock purchase or sale?

The transaction is neither a traditional purchase nor a sale. It is coded “M” for exercise or conversion, indicating 92 RSUs were converted into 92 common shares. No open-market buying or selling price is shown, and the price per share is reported as 0.0000 in the filing.

What vesting schedule applies to the Valion Bio (VBIO) CFO’s Restricted Stock Units?

The RSUs vest over three years starting from December 18, 2024. Half vested on the first anniversary, and the remaining units vest in eight equal quarterly installments. This schedule gradually delivers common shares as long as service and any award conditions continue to be met.

Does the latest Valion Bio (VBIO) Form 4 show remaining derivative or option positions for the CFO?

The derivative section shows the Restricted Stock Units that were partially converted, with 551 RSUs left after the transaction. The filing’s derivative summary is otherwise empty, suggesting no additional derivative positions are detailed in this specific report beyond the RSU award disclosed.